Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)-Reference-Cited by-同舟云学术

Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)

Published:2019-06-07 Issue:1 Volume:20 Page:
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Lennox Belinda,Yeeles Ksenija,Jones Peter B.,Zandi Michael^ORCID,Joyce Eileen,Yu Ly-Mee,Tomei Giuliano,Pollard Rebecca,Vincent Sally-Anne,Shimazaki Mio,Cairns Iona,Dowling Francis,Kabir Thomas,Barnes Thomas R. E.,Lingford Hughes Anne,Hosseini Akram A.,Harrower Timothy,Buckley Camilla,Coles Alasdair^ORCID

Funder

Medical Research Council

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1186/s13063-019-3336-1.pdf

Reference27 articles.

1. Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015;29(2):97–115.

2. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7.

3. Needham E, Zandi MS. Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer’s disease, traumatic brain injury and schizophrenia. J Neurol. 2014;261(10):2037–42.